

Sêmeia has raised €21 million to expand its remote patient monitoring footprint and accelerate its external growth strategy

Paris, 11th May 2026 – New pathologies, AI potential, external growth: Sêmeia, the French leader in remote patient monitoring, has completed a €21m funding round with European funds, giving it the resources to achieve its ambitions.

Having achieved profitability and large-scale deployment of remote monitoring in nephrology, Sêmeia is now strengthening its capabilities to:

- expand its offering to healthcare professionals by addressing new pathologies and delivering innovative services for both care and clinical research;
- pursue its external growth strategy following two successful acquisitions.

“This funding round opens a new chapter in Sêmeia’s journey. It strengthens our teams’ ability to support healthcare professionals and patients. We are also delighted to welcome new partners who are fully aligned with our ambition to generate a concrete and lasting impact on the healthcare system.” **Pierre Hornus, CEO of Sêmeia.**

A LEADING SOLUTION FOR REMOTE MONITORING WITH PROVEN OUTCOMES

The growing prevalence of chronic diseases, which is expected to affect up to 16 million patients and account for 75% of the health budget in France alone by 2035, coupled with the ongoing shortage of healthcare professionals, challenges the entire health system. Remote patient monitoring is now recognized as a key driver to optimize care pathways, benefiting health professionals, patients, and the overall efficiency of the healthcare system.

With over 35,000 patients monitored across 500 healthcare facilities, the Toulouse-based company is the leading French solution for multi-pathology remote monitoring.

Its data-driven medical device, MedicWise, is already active in the fields of nephrology, transplantation, mental health, and cardiology, providing practitioners with automatic collection, structuring, and display of outpatient data as well as the generation of highly targeted alerts.

In nephrology, where Sêmeia is the go-to solution, remote patient monitoring has proven to offer both clinical and organisational benefits: a 26% reduction in patients’ hospitalisations and a 73% reduction in physicians’ time¹.

Almost a third of patients followed up by Sêmeia live in areas with limited access to healthcare, demonstrating its active contribution to reducing regional disparities in access to care.

SETTING A NEW CHAPTER: SETTLE MULTI-PATHOLOGY TELEMEDICINE AS A STANDARD FOR HEALTH PROFESSIONALS AND PATIENTS

¹ Christophe Mariat, Miriana Dinic, Damien Thibaudin, Nicolas Maillard, #2096 A randomized controlled study of telemonitoring in kidney transplantation: interim results of the ApTX trial, *Nephrology Dialysis Transplantation*, Volume 39, Issue Supplement_1, May 2024, gfae069–0092–2096, <https://doi.org/10.1093/ndt/gfae069.092>

Sêmeia is now focusing on the large-scale roll-out of remote patient monitoring products across multiple pathologies, such as mental health conditions like bipolar disorder and depression, type 2 diabetes, IBD, or chronic liver diseases.

The first medical studies have already revealed significant improvements when using MedicWise, such as a 50% reduction in suicide attempts and a 41% reduction in emergency hospitalisations of patients with bipolar disorder.

AN AMBITION TO SCALE UP TELEMONITORING AND CONSOLIDATE THE EUROPEAN E-HEALTH MARKET

With this new funding, Sêmeia aims to intensify its position as a leader within the European healthcare system.

Support the successful rollout of telemonitoring for new pathologies.

Sêmeia is planning to drive new medical studies with the support of clinical experts to validate the positive impact of telemonitoring in new pathologies ahead of its market entry. Some are already underway (e.g., in gastroenterology), with more to follow.

Strengthen investments in data-driven innovation through AI technologies for care and research.

Sêmeia is committed to integrating new AI-driven features to enhance software performance continuously and optimise the organisation of medical follow-up. This effort will also support the company's contribution to over fifteen medical research projects conducted in partnership with clinical teams.

Confirm its position as a key player in the telemedicine market through partnerships and targeted acquisitions.

Sêmeia will pursue a strategy of partnerships and selective acquisitions to improve user experience and the integration of digital solutions into care pathways. After two strategic acquisitions – Optim'Care in 2022 and Healabs in 2025 – several new discussions are already in progress.

COMMITTED INVESTORS SUPPORTING HIGH-IMPACT MEDICAL INNOVATION

This fundraising brings together investors who are recognised for their commitment to technological innovation and impact-driven companies. These include the German fund Acton Capital, and French impact investment funds, Mutuelles Impact (a fund initiated by Mutualité Française and managed by XAnge in partnership with Impactivist), and Citizen Capital. Historical investors, Banque des Territoires (Groupe Caisse des Dépôts) – for which the operation fully aligns with the implementation of the "Santé et Grand âge" roadmap of the Caisse des Dépôts Group, committing €25 billion over a 5-year period - and Orange Ventures, have also renewed their commitment alongside Sêmeia.

"We are very happy to take an active part in the support of Sêmeia's technical expertise and in its ambition to deliver high-impact digital health services. By leveraging innovative technologies, Sêmeia is supporting healthcare professionals and patients for better care while contributing to the efficiency and sustainability of the healthcare system." **Sebastian Wossagk, Managing Partner, Acton Capital.**

Founded in 2017 in Toulouse, Sêmeia offers MedicWise, a platform for the automatic collection and processing of health data, providing an innovative approach to patient follow-up: both in consultation and remotely, without overburdening patients or care teams. Designed in collaboration with healthcare professionals, it combines medical expertise and data science to optimise care pathways, benefiting clinicians, patients, healthcare facilities and the health system as a whole. Our purpose? To help healthcare professionals more effectively support their patients living with chronic conditions.

About Acton Capital

Acton Capital is an international venture capital firm located in Munich and Vancouver. Since 1999, the team has invested in technology-based business models from Europe and North America. With over two decades of experience and a deep understanding of digital transformation, Acton Capital has already supported over 100 startups in building successful businesses. In the healthtech space, Acton has backed companies like Hublo (France, exited 2025), Maple (Canada), and Eolas Medical (UK), driving innovation in healthcare HR, telemedicine, and clinical knowledge infrastructure.

About XAnge

XAnge is a B Corp-certified early-stage investment fund with €800m under management and offices in Paris, Berlin and Brussels. The fund backs European founders aiming to transform everyday life through technology, investing between €1m and €15m from seed through Series C. XAnge is the venture capital brand of the Siparex group.

About Mutuelles Impact

Created in 2020 at the initiative of Mutualité Française, managed by XAnge in partnership with Impactvist, Mutuelles Impact is the first impact fund dedicated to healthcare. Its objective is to invest in high-impact companies and support them in the areas of prevention, new care pathways, and medico-social services. With over €95m under management, the fund is backed by 64 French health insurers and 3 territorial actors (Banque des Territoires, Eurométropole de Strasbourg and e-Meuse santé).

About Citizen Capital

Citizen Capital is a pioneering impact investment firm founded in 2008. Its mission is to mobilise capital to address the social and environmental challenges of our time. An independent firm approved by the AMF, it manages €376M across 3 strategies: growth, agriculture and social economy. Citizen Capital has invested in several landmark impact companies in France and Europe, including Karos, OpenClassrooms, Deepki, Ipso Santé and Hubcycle. A mission-driven company, it is B Corp certified, a signatory of the UN-PRI and a founding member of the "Communauté des entreprises à mission". www.citizencapital.eu.

About Banque des territoires (Groupe Caisse des dépôts)

Banque des Territoires is one of the entities of the Caisse des Dépôts. Banque des Territoires brings together in-house expertise for local areas. As a one-stop shop for customers, it acts alongside all local stakeholders: local authorities, local public-sector enterprises, social housing bodies, legal professions, businesses and financial players. Banque des Territoires assists them in the implementation of their public interest projects with a continuum of offers: advisory, loans, equity, bank services, consignments and special deposits. It has been set up to serve the interests of all local areas alike, from rural municipalities to large cities, with the ambition of maximizing its impact notably on ecological transformation and social and regional cohesion. The 37 territorial offices of Banque des Territoires ensure the implementation of its action across all metropolitan and overseas territories.

Act together to develop more eco-friendly and socially responsible territories.

banquedesterritoires.fr

About Orange Ventures

Orange Ventures is the corporate venture capital arm of Orange Group, one of Europe's leading telecommunications operators. The fund invests in early to growth-stage startups that operate at the intersection of connectivity, digital infrastructure, and emerging technologies. Beyond capital, Orange Ventures acts as a strategic partner, offering startups privileged access to Orange's distribution channels, enterprise client base, and technical infrastructure to accelerate their commercial growth.

Orange Ventures has developed a dedicated focus on the digital health sector, investing in startups leveraging connectivity, AI, and data to reshape patient care, clinical workflows, and health system efficiency areas where Orange's technological backbone provides a natural competitive advantage for portfolio companies.

Press Contacts

Phoenix Coms&Co - Laurence Simon

M : laurence.simon@phoenix-coms.fr – T : 06 18 67 04 08